Company: CORT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001628280-25-019942
Chunk: 28

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 28
---
 above. These include: (i) increasing our revenue; (ii) submitting an NDA to the FDA for relacorilant to treat patients with hypercortisolism; (iii) achieving positive results in CATALYST, our Phase 4 trial examining the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and its treatment with Korlym; (iv) completing enrollment in ROSELLA, our pivotal Phase 3 trial of relacorilant combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer; (v) completing enrollment in DAZALS, our Phase 2 trial of dazucorilant in patients with amyotrophic lateral sclerosis (“ALS”); (vi) continuing enrollment in MONARCH, a Phase 2b trial of miricorilant in patients with MASH; and (vii) continuing enrollment in a Phase 2 trial of relacorilant combined with enzalutamide, in patients with prostate cancer.

In light of these accomplishments, the Compensation Committee recommended, and the Board approved, the payment of bonuses to all employees of the Company, including payments to our named executive officers as set forth below.

| Executive                |     | Target Bonus Achievement 
 (%)                      |     | Bonus Amount 
 ($)          |           |
|:-------------------------|:----|:-------------------------|:----|:-------------|----------:|
| Joseph K. Belanoff, M.D. |     | 150%                     |     | $            | 1,716,000 |
| William Guyer, Pharm.D.  |     | 155%                     |     | $            |   510,198 |
| Sean Maduck              |     | 150%                     |     | $            |   471,120 |
| Atabak Mokari            |     | 150%                     |     | $            |   411,060 |
| Charles Robb             |     | 155%                     |     | $            |   533,572 |

<div align='center'>17</div>

Long-Term Equity Incentive Program

We believe that equity incentives motivate outstanding performance from our employees by linking a portion of their compensation to the performance of our stock. Our employees are eligible to receive grants of restricted stock and stock options under our 2024 Incentive Award Plan (“2024 Plan”). With respect to our named executive officers, we have used